Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GUSB | P08236 | 2/20 | 0.30 |
| ▸ | EBP | Q15125 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4362539 | 0.98 | TSHR (0.36) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL29249978 | 0.98 | TSHR (0.36) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1680335 | 0.98 | TSHR (0.34) | TSHRALDH1A1GUSBEBPSIGMAR1 | |
| Hydrochloric Acid SCHEMBL28958784 | 0.96 | TSHR (0.33) | TSHRALDH1A1GUSBEBPSIGMAR1 | |
| SCHEMBL15901603 | 0.96 | TSHR (0.38) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL2693560 | 0.96 | TSHR (0.38) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3398654 | 0.96 | TSHR (0.38) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL4358564 | 0.96 | TSHR (0.38) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL28380752 | 0.95 | TSHR (0.36) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Iodide SCHEMBL2894608 | 0.95 | TSHR (0.36) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1721900-B1 | NOVEL IMIDAZOLIUM COMPOUND | KANTO KAGAKU (JP) | 2014-06-11 | — | — | EP | disclosed |
| US-7517999-B2 | needs no complicated operations for dissolution and has excellent handleability and a high ionic conductivity, electrolytes; 1-butyl-3-allylimidazolium bromide | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070191612-A1 | Needs no complicated operations for dissolution and has excellent handleability and a high ionic conductivity, electrolytes; 1-butyl-3-allylimidazolium bromide | HIROYUKI OHNO (JP) | 2007-08-16 | — | — | US | disclosed |
| CN-1922152-A | Novel imidazolium compound | KANTO KAGAKU (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1721900-A1 | NOVEL IMIDAZOLIUM COMPOUND | Kanto Kagaku Kabushiki Kaisha (JP) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191612-A1 | Needs no complicated operations for dissolution and has excellent handleability and a high ionic conductivity, electrolytes; 1-butyl-3-allylimidazolium bromide | SLC26A3, KCNJ11, SLC26A4 | SIGMAR1 2593/4885TSHR 1992/4885ALDH1A1 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.